Biohaven Pharmaceutical Holding Pre-Tax Profit Margin 2016-2022 | BHVN

Current and historical pre-tax profit margin for Biohaven Pharmaceutical Holding (BHVN) from 2016 to 2022. Pre-tax profit margin can be defined as earnings before taxes as a portion of total revenue. Biohaven Pharmaceutical Holding pre-tax profit margin for the three months ending March 31, 2022 was .
Biohaven Pharmaceutical Holding Pre-Tax Profit Margin Historical Data
Date TTM Revenue TTM Pre-Tax Income Pre-Tax Margin
2022-03-31 $0.74B $-0.68B -91.46%
2021-12-31 $0.46B $-0.84B -182.29%
2021-09-30 $0.31B $-0.86B -278.25%
2021-06-30 $0.19B $-0.88B -460.53%
2021-03-31 $0.11B $-0.85B -792.52%
2020-12-31 $0.06B $-0.76B -1184.38%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $10.111B $0.463B
Biohaven Pharmaceutical is a commercial-stage biotechnology company focused on developing, and commercializing products, primarily in the fields of central nervous system diseases, including neurological and rare disorders.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $162.107B 9.86
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.761B 16.99
Ginkgo Bioworks Holdings (DNA) United States $5.648B 0.00
Emergent Biosolutions (EBS) United States $1.770B 7.57
Arcus Biosciences (RCUS) United States $1.376B 34.89
Myovant Sciences (MYOV) United Kingdom $1.033B 0.00
Zymeworks (ZYME) Canada $0.397B 0.00
Gelesis Holdings (GLS) United States $0.345B 0.00
Ambrx Biopharma (AMAM) United States $0.157B 0.00
Enzo Biochem (ENZ) United States $0.110B 22.60
SQZ Biotechnologies (SQZ) United States $0.100B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00